

UK Life Science



BIO-EUROPE

Leipzig

24-27 October 2022



| Internationalising UK Life Sciences



UK delegation profiles and attending UK-based companies

BioPartner UK Delegations

Showcasing UK Life Science

BioPartner UK Delegations promote the UK presence at international conferences. We work with conference organisers, in-country agencies and overseas networks to provide the best discounts and business opportunities for UK companies travelling with the Delegation.

Representation on the UK exhibition stand

- Literature and business card display
- Your company logo displayed
- Optional pull-up display or full exhibit stand

Increased visibility as part of the group

- Profile in online and printed directory
- UK lapel pins for group members

Networking and referrals

- Pre-event networking/briefing session

Organisational assistance

- Conference booking, freight, itinerary
- Pre-paid hotel close to the venue with discounts
- Back-up: battery charging, disaster recovery

UK Delegation members gain significant extra promotion and networking opportunities at many of the biggest biopharma partnering events. BioPartner UK also provides access to government grants and enhanced entry fee discounts for UK-based SMEs.

Our delegates say:

"It's great to have a central meeting point and the added benefit of introductions from BioPartner to others in the network."

"Being able to join the excellent UK Delegation, to receive representation on the UK stand, which is always a point of interest for attendees."

"The UK delegations are very helpful and offer good support to the companies involved."

Introduction

We are delighted to bring 35 UK companies to Leipzig for BIO-Europe 2022, and to support an additional 205 who are independently registered* for this first face-to-face BIO-Europe in three long years.

We have National Institute for Health and Care Research (NIHR) exhibiting with us again this year. **Come and visit us at Booth 19** to find out more about UK expertise and make contact with companies attending from the UK.

At BIO-Europe 2022, we have around 240 companies from the UK at the event looking to forge profitable relationships, and joining us in the UK exhibition area are Random42 and CHASE. The UK is a natural trading partner for life sciences companies looking for innovative collaborations, access to academic excellence and entry to the Europe and other global destinations.

The UK is one of the world's strongest and most productive life sciences economies; it attracts almost 10% of the world's pharmaceutical R&D funding and provides a uniquely fertile environment for the life sciences industry where businesses thrive. Innovation flourishes and is easy to commercialise; industry collaborates with academia and the health service; people are highly skilled, and it is a leading investment location for life sciences businesses, that continues to thrive in a changing world.

International representatives from BioPartner UK, Department for International Trade, UK Bioindustry Association, MediWales, One Nucleus, OBN, Scottish Development International, Invest Northern Ireland, and NIHR will be available at BIO-Europe 2022 and we will all be very happy to discuss how we can help maximise your business potential. Come and have a cuppa with us at booth 19!



*numbers correct at time of print

BioPartner UK



Exhibiting at booth 19 with the UK delegation

BioPartner UK leads the UK Delegation to several partnering conferences each year. It is a UK Accredited Trade Organisation facilitating international partnering for trade, investment and collaborations with Life Sciences organisations across the UK. BioPartner is a membership organisation, supporting UK SMEs and startups, and signposting organisations worldwide to UK expertise.

BioPartner has alliances with organisers of international biopartnering events, and with UK membership organisations, operating both independently and in partnership with the UK government. BioPartner disseminates tradeshow access grants to help UK-based SMEs exhibit their services and products in new overseas markets.

We will be serving tea throughout the event: Teapigs, Clipper and Yorkshire – with biscuits for as long as they last!

On Monday evening in partnership with Scottish Development International we host a Scotch Malt Whisky tasting, and you can win a bottle of Shortcross Gin courtesy of Invest Northern Ireland at our regional gin tasting session.

See the back cover for more details.

www.biopartner.co.uk

Ms Finlay Lynch Marketing Manager

Ms Emma Kosci-Martin Events Manager

Ms Paula Paton Member Services Coordinator

Dr William Watson Board Member

UK Department for International Trade



The UK Government's Department for International Trade is here to support companies looking to explore opportunities in the UK's vibrant life sciences sector. Whether you'd like to learn more about R&D in the UK, partnerships, funding, setting up a UK company or using the UK as a base to internationalise, we are here to help you navigate the UK ecosystem

<https://www.gov.uk/government/organisations/department-for-international-trade>

William Lindsay *Sector Specialist Life Sciences*

Hannah Williams *Deputy Head of Life Sciences - Biopharmaceuticals*

Scottish Development International (SDI)



Scottish Development International (SDI) is part of Scotland's main enterprise, innovation and investment agency and works to help international companies find partners in Scotland and Scottish companies develop their business overseas. SDI also works to attract inward investment and knowledge to Scotland in order to help the economy grow.

SDI has a network of offices around the world and provides a wide range of support services covering each phase of international activity, including: identifying potential partners, scoping financial incentives, R&D grants, business mentoring, market intelligence, business location information and investor aftercare.

The Scottish Life Sciences sector counts more than 700 organisations and 35,000 people with particular strengths in supporting drug discovery and development, regenerative medicine/stem cells, animal health, medical devices, digital health and clinical translational medicine.

<http://scotent.co.uk>

Katharina Kraehahn *Senior Executive*

Nils Roehrer *Senior Executive*

UK Delegation

Members of the UK delegation are listed alphabetically with profiles, followed by a list of UK-based organisations (by company name and then by company type) attending the conference.

All of these companies can be contacted via their business cards or by leaving a message at booth 19 with BioPartner staff.

Whereas every effort has been made to ensure that the information given in this document is accurate, BioPartner UK accepts no liability for any errors, omissions or misleading statements, and no warranty is given or responsibility accepted as to the standing of any individual, firm, company or other organisation mentioned. All UK companies registered up to 14th October are included.

Almac Discovery Ltd



Almac Discovery is a research driven drug discovery company operating within the Almac Group dedicated to the development of novel and innovative approaches to the treatment of diseases of unmet need (including oncology and CNS). Our business model is primarily to discover and develop novel First-in-Class drug candidates through to pre-clinical development, and then to seek pharmaceutical or biotech partners for clinical development and commercialisation. Key research themes are two-fold: a) Controlling protein homeostasis through targeting Deubiquitinase (DUB) enzymes, and, b) Generating novel protein drug conjugates (PDCs) utilising single chain antigen recognition domains linked to Almac's proprietary linker:payload technology.

Website: almacgroup.com

Company type: R&D

Alan Lamont *VP Business Development and Licensing*

Almac Group



The Almac Group is an established contract development and manufacturing organisation that provides the most unique range of integrated drug development services available to the pharmaceutical & biotech industry.

Website: almacgroup.com

Company type: D&D SERVICES

Maciej Krause *Business Development Manager – EU*

Peder Fode *Business Development Manager*

Bit Bio



Our breakthrough technology combines synthetic and stem cell biology, offering limitless possibilities. Enabling a new generation of cell therapies, providing the best human cells for research and drug discovery, and allowing the control of advanced synthetic biology circuits for biomanufacturing.

Website: bit.bio

Company type: PHARMATECH

Kam Dhaliwal *Global Senior VP Alliance Management*

Charnwood Molecular



Charnwood Molecular is an integrated drug discovery provider with a 25-year track record of delivery to our clients worldwide, many of whom are emerging pharmaceutical companies. We believe in bringing together the right experts, technologies, capabilities, and passion, to support customer drug discovery projects and deliver potent, selective, and drug-like candidates.

Our experienced project scientists (medicinal chemistry, biology, computational chemistry, ADME/PK and process chemistry) understand the drug discovery process, the importance of physicochemical properties, the interrogation of biological data and generation of SAR, with expertise in all major disease areas and targets. Our **world-class laboratory facility** at Charnwood Campus, is the **single location** of all our drug discovery experts and resources.

Website: charnwood-molecular.com

Company type: PHARMATECH

Linós Lazarides *Senior Business Development Executive*

CHASE



We are a leading provider of outsourced commercial, medical and recruitment services to pharmaceutical, biotech and healthcare companies. Working exclusively in the United Kingdom, we have brand strategy, implementation, and recruitment experience from numerous launches across prescription medicines, medical devices, and medical software. We provide a UK launch solution for pharmaceutical, biotech and medtech companies, that is an alternative to out-licensing and traditional distribution arrangements.

Website: chasepeople.com **Company type:** SERVICE

Richard Baderin *Head of Brand Strategy and Management*

Richard Grethe *Non-Executive Director*

Curileum Discovery



Curileum is a biotechnology company in London that focuses on discovering and developing novel therapeutics to intervene early in the development of severe GI diseases. With a dynamic team of scientists committed to translating our science to game-changing therapies, we have discovered and delivered two first-in-class preclinical therapeutic candidates and a compelling novel drug target.

ULI-015 a small molecule to reduce polyp formation and progression to bowel cancer. ATZ stem cell therapy to repair an incurable condition in Crohn's disease patients. CSR-1 a soluble regulator in Crohn's patients that drives chronic gut inflammation.

Curileum is seeking co-development and licensing partners for its two de-risked, first-in-class preclinical therapeutic candidates and a collaboration partner to develop a small molecule antagonist to our novel drug target driving chronic gut inflammation.

Website: curileum.com

Company type: R&D

Veronica Gray *Senior Business Development Manager*

Evgen Pharma



Evgen Pharma is a clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases.

The Company's core technology is Sulforadex[®], a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The Company's lead asset, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin and has undergone clinical trials for oestrogen-positive (ER+) metastatic breast cancer. In September 2021 the FDA granted Orphan Drug status to SFX-01 in malignant glioma.

The Company also has a wide number of collaborations with leading academic centres in the UK, Europe and AsiaPac as part of the continuing strategy to build the data set of safety and efficacy around the compound. With respect to non-core area, Evgen signed an outlicensing deal with JuvLife, the dietary products and functional foods division of Juvenescence Ltd, for the development of a naturally-sourced sulforaphane nutritional health supplement, stabilised using Evgen's Sulforadex[®] technology.

The Company has its headquarters and registered office at Alderley Park, Cheshire. It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG.

Website: evgen.com

Company type: R&D

Helen Kuhlman *Chief Business Officer*

Huw Jones *Chief Executive Officer*

Fusion Antibodies



Established in 2001, Fusion Antibodies is a Collaborative Research Organisation (CRO) with its headquarters in Northern Ireland. We are world leaders in antibody development services specializing in the discovery, engineering and supply of pre-clinical biologics to clinical Cell Line Development. We have guided hundreds of projects through critical pre-clinical stages, repeatedly proving our expertise as we strive to bring about a positive change in the healthcare industry.

Our approach to engineering and optimization is often to harness the power of the natural somatic hypermutation space. Fusion offers flexibility and agility while delivering clinical candidates focusing on developability, manufacturability and function.

Fusion has developed a number of unique, proprietary technology platforms. Our suite of development capabilities include:

- Antibody humanization (CDRx™)
- Affinity maturation (RAMP™)
- Protein engineering
- Discovery (mouse hybridoma and rabbit B cell approaches)
- Protein production – CHO and other mammalian systems
- Cell Line Development – cGMP ready mammalian cell lines
- Expert scientific & technical advisory services
- Bespoke & collaborative large-scale R&D programs

Website: fusionantibodies.com

Company type: D&D SERVICES

Adrian Kinkaid *CEO*

Brett Whitecross *Alliance Director*

InSilicoTrials has built an online platform, where Modeling & Simulation is easy to use, regulatory compliant, and cost-effective.

Today, Modeling and Simulation can help companies reduce the very long and expensive development, as well as the subsequent registration/certification processes for new drugs and medical devices up to 50% and greatly accelerate the go-to-market of new products, allowing companies to exploit patents for a longer period.

InSilicoTrials solves these problems by selecting and collecting the best models from top researchers around the world and then by integrating them with the solvers in a scalable IT platform, which makes it easier to use validated models without specific computational knowledge, paying only for the used resources. We cover the entire process with the in silico approach, from preclinical to clinical. Our product portfolio covers a wide range of therapeutical areas and allows our customer to customise the way they want to work with us. In silico trials allow to get in a few minutes or hours, instead of weeks, outcomes that are more reliable and already compliant with regulatory guidelines.

Website: insilicotrials.com

Company type: D&D SERVICES

Luca Emili *CEO*

Mario Torchia *VP sales and marketing*

LSX



LSX is a growing influential community of senior life science decision makers, and are a catalyst for dialogue, debate and deal making to help lead growth in healthcare investment and the building of billion pound healthcare businesses. LSX is determined to forge a fundamentally better way to promote and facilitate investment, financing, partnerships and deal making in healthcare. Their community helps catalyse early stage innovation through peer-to-peer education and knowledge sharing, networking, partnering and deal making to champion the most innovative and exciting ideas.

Website: lsxleaders.com

Company type: NETWORK

Tom Roberts *Vice President*

Melanie Lang *Senior Business Development Manager*

Ceri Doyle *Business Development Manager*

Medherant



MEDHERANT

Medherant develops patches for transdermal drug delivery using our proprietary TEPI-Patch® technology. Key advantages of the TEPI Patch® technology over current technologies include excellent adhesion that can be tailored for up to 7-days of drug delivery, whilst still being easy and painless to remove. No organic solvents are involved in manufacture of this drug-in-adhesive system. As well as developing our own products, some of which have already been successfully tested in clinical studies, Medherant is working with pharmaceutical companies to develop new products. We are seeking additional partners and can offer rapid feasibility studies using our proprietary high throughput permeation study system to develop transdermal formulations of drugs of interest.

Website: medherant.co.uk

Company type: R&D

Nigel Davis *Chief Business Officer*

MediWales



MediWales is the life science network and representative body for Wales. An independent, not-for-profit organisation that is owned by its members, MediWales provides advice, support, business opportunities and promotes collaborations for the life science and health technology community in Wales.

MediWales delivers an extensive events programme, including the UK HealthTech conference and the MediWales Innovation Awards and produces a number of publications including UK Lifescience Industry magazine, the Annual Directory and Review, and case study magazine LifeStories. MediWales promotes and supports its members in Wales, across the UK and internationally.

Website: mediwales.com

Company type: NETWORK

Debbie Laubach *Operations Manager*

Mironid Limited



Mironid develops proprietary drug candidate molecules that act by selectively modulating the activity of the key cell signalling enzyme PDE4. The focus of the company's activities are predominantly in two key portfolio programs :

1. LoAc - First in class opportunity for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
2. ShoLo – Best in class opportunity for the treatment of chronic inflammatory diseases. Both programs are currently moving to candidate nomination and initiation of formal preclinical development.

Website: mironid.com

Company type: PHARMATECH

Neil Wilkie *CEO*

National Institute for Health and Care Research (NIHR)



The NIHR (National Institute for Health and Care Research) enables, funds and delivers world-class health and care research that transforms people's lives, advances science globally and benefits the UK economy.

The NIHR:

- Engages and involves patients, carers and the public in order to improve the reach, quality and impact of research
- Attracts, trains and supports the best researchers to tackle the complex health and care challenges of the future
- Invests in world-class infrastructure and a skilled delivery workforce to translate discoveries into improved treatments and services
- Partners with other public funders, charities and industry to maximise the value of research to patients and the economy

Website: nhr.ac.uk

Company type: R&D

Elizabeth Atkinson *Events and Marketing Assistant*

Karen Matthews *Business Development Manager*

Natalie Wilson *Business Development Manager*

Alicia Cox *Business Development Manager*

Sajni Haria *Business Development Manager*

Oncimmune



Oncimmune, a global leader in immunodiagnostics and (auto) antibody biomarker profiling & discovery in immuno-oncology, autoimmune and infectious diseases. Through its ImmunoINSIGHTS™ technology platform, the company provides insights to discover and validate novel biomarkers, improve treatment responses and adverse event (irAE) prediction, patient screening and diagnostic accuracy. Oncimmune is headquartered in the UK with operations in Germany and USA.

Website: oncimmune.com

Company type: D&D SERVICES

Mike Fisher *Vice President, Head of Business Development*

Mathilde Perucchon *Business Development Manager*

Oppilotech Ltd



Oppilotech develops first-in-class drugs. We believe that target selection is the most important decision we make in drug discovery – a selective high-quality molecule will never become a drug if it is modulating the wrong target.

Oppilotech has developed a high-resolution platform based on systems biology and machine learning to model biological processes in cells. The platform is utilized to identify first-in-class drug targets and to develop novel modes of action drugs modulating the identified targets.

We undertake both the target selection and develop the drugs against the identified target. We initially focused our modelling efforts on E.coli identifying several first-in-class antibacterial drug targets and generated active chemical matter against them.

Oppilotech Ltd continued...

The company intends to develop these programmes towards the clinic. We are now expanding into pathways in human cells allowing us to address a wider range of diseases including cancer (e.g. DNA Damage Response) and inflammation.

Website: <http://oppilotech.com/>

Company type: R&D

Ajay Mistry *Founder/CEO*

Pebmond Associates



Pebmond Associates – whether you consider your project or company a Pebble or a Diamond – Our strategic advice and business services for life-science and healthcare organisations adds “Multifaceted Value®”.

Strategy, Business Development and Licensing is our focus – whether it is support to acquire, divest or license a product or project - independent eyes and ears on your company strategy, direction, future plans, project prioritisation or even just general brainstorming – or building your team’s skills in these areas by coaching, face-to-face training, lectures, webinars or e-learning.

We do all that - and more importantly, smile at the same time.

Website: pebmonduk.com

Company type: SERVICE

William Watson *Executive Director*

Precision for Medicine



Precision for Medicine is an industry-leading global CRO designed specifically to apply a biomarker-focused, precision medicine approach to therapeutic development.

What sets us apart is an end-to-end harmonized interconnected approach to novel and adaptive laboratory and translational research and complex biomarker trials coupled with expertise in kit development, logistics, and sample management, and data sciences.

This convergence of trials, labs, and data sciences is driving faster clinical development and approval. We apply our expertise to trials at all stages, from early development through approval.

Website: <https://www.precisionformedicine.com/>

Company type: D&D SERVICES

Andre Bongartz *Director, Strategic Development*

UK BioPartner UK adds a little extra

Turn your solo delegate experience

Into a supportive network

The graphic features the UK flag logo and the text "BioPartner UK adds a little extra". Below this, two photographs illustrate the concept: the left photo shows a single man in a suit walking through a trade show, and the right photo shows a group of people in business attire gathered around a booth, engaged in conversation. The BioPartner logo is located at the bottom right of the graphic.

The BioPartner logo, featuring the word "BioPartner" in blue with a red stylized figure of a person running or jumping above the "o".

Random42



Random42 provides scientific digital solutions to the pharmaceutical, medical device and diagnostics industries with its award-winning medical device animation, virtual reality, augmented reality and interactive solutions.

Website: random42.com

Company type: SERVICE

Liam O'sullivan *Head of I.T.*

Naomi Carlow *Senior Account Executive*

Ms Joanna Hare *Account Manager*

Research Donors Ltd



Research
DONORS

Research Donors collects, processes and delivers human blood biospecimens that meet the most demanding research requirements.

With a diverse community of over 2500 donors, we can meet any donor specification as required by your project. Fresh HLA typed human leukopaks, PBMCs, whole blood and blood derivatives, all consented for commercial and genetic research, can be delivered within 24 hours of collection across Europe.

Website: researchdonors.co.uk

Company type: SERVICE

Vashu Pamnani *Senior Business Manager*

Rosemont Pharmaceuticals



Our ambition has always been to support both patients with swallowing difficulties and the healthcare professionals who care for them. We are highly respected in the industry and have been instrumental in establishing best practice for the care of patients with swallowing difficulties. Rosemont advocate the use of liquid medication over manipulating solid dose medications and we have a range of educational materials designed for healthcare professionals which focuses on key patient groups and their medication management challenges.

Website: rosemontpharma.com

Company type: PHARMA

Rupert Sargeant *International Sales and Out-Licensing Manager*

Scendea



Scendea is a leading product development and regulatory consulting practice serving the pharmaceutical and biotechnology industry. Our international team offers strategic and operational support in the fields of quality/CMC, non-clinical/toxicology, clinical/medical and regulatory, which guide products efficiently from early development to marketing approval. Our scientific excellence, industry experience, commercial awareness and a collaborative approach allow our expert team to solve complex issues associated with medicinal product development. Scendea has team members based in the UK, Ireland, the Netherlands and the US, who deliver innovative and high-quality solutions aligned to jurisdiction-specific regulatory requirements. At Scendea we collaborate, innovate, and together with our clients, we succeed.

Website: scendea.com

Company type: SERVICE

Paul Cronin *Director*

Stuart Hunter *Senior Business Development Manager*

Silence Therapeutics plc



Silence Therapeutics develops a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells.

Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.

Website: silence-therapeutics.com

Company type: R&D

Joana Santos *Senior Business Development Manager*

Somaserve



SomaServe's PolyNaut platform addresses the 'delivery problem' for intracellular, targeted delivery of nucleic acid-based therapeutics and protein therapeutics. This includes mRNA, siRNA, pDNA and ASOs. PolyNaut technology addresses shortcomings of viral or lipid-based delivery technologies by encapsulating a range of therapeutic modalities into polymer nanovesicles that are stable in biological conditions, can penetrate biological barriers such as the blood brain barrier effectively, and selectively target different tissues and cell types.

Website: <https://somaserve.com/>

Company type: R&D

Sam Barker *VP Business Development*

UK BioIndustry Association (BIA)



Established in 1989, the BIA (BioIndustry Association) exists to encourage and promote a financially sound and thriving bioscience sector within the UK economy and concentrates its efforts on emerging enterprise and the related interests of companies Founded over 20 years ago at the infancy of biotechnology, the BIA is the trade association for innovative enterprises involved in UK bioscience.


Members include emerging and more established bioscience companies; pharmaceutical companies; academic, research and philanthropic organisations; and service providers to the bioscience sector. The BIA represents the interests of its members to a broad section of stakeholders, from government and regulators to patient groups and the media.

Our goal is to secure the UK's position as a global hub and as the best location for innovative research and commercialisation, enabling our world-leading research base to deliver healthcare solutions that can truly make a difference to people's lives.

Website: bioindustry.org

Company type: NETWORK

George Caterer *Membership & Business Development Manager*



Attending UK Companies

Members of the UK delegation are showcased at the UK stand, booth 19.

Others can be contacted via the PartneringOne online system.

272 Bio Limited, 42 Therapeutics, 4BIO Capital, Abcam, Absolute Antibody, Adaptimmune, Adrestia Therapeutics, Advanced Clinical, Advanz Pharma, Alacrita Consulting, Alchemab Therapeutics, **Almac Discovery, Almac Group**, AlphaSense, Amphista, Antibody Analytics, Apex Healthcare Consulting Limited, Apple Tree Life Sciences (UK) Limited, Aptamer Group, Arecor Limited, Arix Bioscience, Asieris Pharmaceutical, ASKA Pharmaceutical Co, Aspire pharma, Astellas Pharma, Aston Uni, AstraZeneca, Atheneum, Autolus, Avacta Life Sciences Limited, Barrington James, BenevolentAI, Bicycle Therapeutics, BioCentury, Biogen, BioLife Group, Biomage, **BioPartner UK**, Biopharma Excellence by PharmaLex, Biopharma Group, **Bit Bio**, Bristol-Myers Squibb Company, Cancer Research UK, CC Biotech, Charles River Associates, **Charnwood Molecular, CHASE**, Chiesi, Chugai Pharmaceutical Co, Citeline, Clinigen, Coulter Partners, Crescendo Biologics, **Curileum Discovery**, Daewoong Pharmaceutical Co, Department for International Trade, Destiny Pharma, DLRC, Domainex, Drug Development Solutions, éclateral, Edinburgh Molecular Imaging, Eisai Europe, Elasmogen, Eli Lilly and Company, Ellipses Pharma, Emergex Vaccines, EnteroBiotix, Erebagen, Esperante, Essential Pharma, Etcembly, Eurofins Discovery DiscoveryOne, Evaluate, Eversana, **Evgen Pharma**, Evotec International, Evox Therapeutics, Exploristics, Exscientia, F-Prime Capital, Ferghana Partners, Ferring, Forcefield Therapeutics, FUJIFILM Diosynth Biotechnologies, **Fusion Antibodies, Galen**, GlobalData, Gowling WLG, GSK, HealthCare Royalty Partners, Healx, Heptares Therapeutics, HistologiX, HungaroTrial CRO, HVIVO Services Limited - London, IAG (Image Analysis Group), ICR, ImaginAb, ImmTune Therapies, Imspex Diagnostics, IN-PART, Inizio, **InSilicoTrials Technologies**, Intelligent OMICS, invoX Pharma, Ipsen, IsomAb, Jazz Pharmaceuticals, Johnson & Johnson, KBio, Labcorp Drug Development, Life Sciences Recruitment, Lifearc, LifeSci Search, LiliuX, LoQus23 Therapeutics, **LSX, Medherant**, MediMab Biotherapeutics, **MediWales**, MedPharm, Merck, Mereo BioPharma, Mergermarket, MESOX (Spinout from Aston), Microbiotica, Midatech Pharma, Mills & Reeve LLP, ...

Attending UK Companies (continued)

Members of the UK delegation are showcased at the UK stand, booth 19.

Others can be contacted via the PartneringOne online system.

Mironid, MitoRx Therapeutics Limited, Mitsubishi Tanabe Pharma Corporation, Monograph, Monument Tx, MSD, MultiOmic Health Limited, Myonex, Nanomerics, NanoSyrinx, **National Institute for Health and Care Research (NIHR)**, Nevrargenics, Norgine Limited, Norgine Ventures Management Limited, Oak Hill Bio, OBN (UK), Ochre Bio, OMass Therapeutics, **Oncimmune**, One Nucleus, ONO Pharma, **Oppilotech**, Orbit Discovery, Ossianix, Otsuka Pharmaceutical, oval, Owkin, Oxford BioTherapeutics, OxSonics, Parkinson's Research Ventures, **Pebmond Associates**, Pencil Biosciences, Pharma Intelligence, PharmaCircle, Pharmanovia, PHARMASSIST, PharmaVentures, PharmEnable, PhoreMost, Physiomics, Poolbeg Pharma, Pracipio, **Precision for Medicine**, **PrecisionLife**, Present Value Limited, Prokarium, ProPharma Group, Quadram Institute Bioscience, Queen's University Belfast, Quotient Sciences, Rallybio, **Random42**, Radox Laboratories, RBW Consulting, Renata Limited, ReNewVax, **Research Donors**, Results, **Rosemont Pharmaceuticals**, Sartorius Stedim Biotech, **Scendea**, Scius Communications, **Scottish Development International (SDI)**, Scrip, Sekisui, SGS, Shanghai Medicilon, Shionogi, **Silence Therapeutics**, Simbec-Orion, Simcere Pharma, SiSaf, Sitryx, SLA Pharma, **SomaServe**, Sonrai Analytics, Spirea, Springer Nature, Standigm, Sterling Technology, SynOx Therapeutics Limited, T-Cypher Bio, Tanner Pharma, The Fulford Group, The Institute of Cancer Research, The Sage Group, Theramex, tranScrip, Treehill Advisors, Ubiquigent, UCB, UCLB, **UK BioIndustry Association (BIA)**, University of Bradford, University of Dundee, University of Edinburgh, Vaccitech, ValiRx, VaxEquity, Veristat, Vernalis R&D, Virocell, WEP Clinical, WittKieffer International, WuXi AppTec, WuXi Biologics, X-Chem.

(237) correct as of 14th October 2022

Index of UK Company Types

(as selected by themselves in the PartneringOne system)

Biotechnology - Therapeutics and Diagnostics

272 Bio Limited	MedPharm Ltd
42 Therapeutics	Microbiotica
Abcam	Midatech Pharma
Adrestia Therapeutics Ltd	Mironid Ltd
Alchemab Therapeutics	MitoRx Therapeutics Limited
Almac Discovery Ltd	Monument Tx
Autolus	MultiOmic Health Limited
Avacta Life Sciences Limited	Myonex
Bicycle Therapeutics	National Institute for Health and Care Research
Bit Bio Ltd	Oak Hill Bio
Cancer Research UK	OBN (UK) Ltd
CC Biotech Ltd	OMass Therapeutics
Crescendo Biologics Ltd	Oncimmune
Destiny Pharma plc	ONO Pharma
Elasmogen Ltd	OxSonics
Ellipses Pharma Ltd	PhoreMost Ltd
EnteroBiotix	Present Value Limited
Erebagen	Quadram Institute Bioscience
Etcembly	Spirea Ltd
Evgen Pharma	Sterling Technology
Evgen Pharma plc	SynOx Therapeutics Limited
Healx	The Fulford Group
Heptares Therapeutics Ltd	The Sage Group
IN-PART	UK BioIndustry Association (BIA)
invoX Pharma	University of Bradford
IsomAb Ltd	ValiRx PLC
Johnson & Johnson	Vernalis R&D Ltd
Life Sciences Recruitment	Virocell
LoQus23 Therapeutics Ltd	WEP Clinical
LSX	

Investors

Apple Tree Life Sciences
HealthCare Royalty Partners
Pebmond Associates

Prof Services & Consulting

Alacrita Consulting
Citeline
Coulter Partners
DLRC Ltd
Evaluate
Eversana
Ferghana Partners
Inizio
Intelligent OMICS
Lifearc
Medherant
Pharmanovia
PharmaVentures Ltd

Medical Technology

Oxford BioTherapeutics
Parkinson's Research Ventures
Quotient Sciences Ltd.

PharmEnable
Prokarium
Rosemont Pharmaceuticals
SciUS Communications
Scottish Development Int.
Scrip
Springer Nature
T-Cypher Bio Ltd
The Inst.of Cancer Research
Theramex
Treehill Advisors LLP
Ubiquigent

Pharma

BenevolentAI
Eisai Europe Ltd
Galen Ltd
Orbit Discovery Ltd
Pracipio Ltd
SomaServe
WittKieffer International
Advanz Pharma
KBio
Arecor Limited
PrecisionLife
Aspire pharma ltd

Exscientia
tranScrip Ltd
Scendea Ltd
Barrington James
NanoSyrinx Ltd
SLA Pharma
AstraZeneca
Shanghai Medicilon Inc.
Randox Laboratories
Clinigen
Research Donors Ltd
Physiomics plc
Biopharma Group

Supplier & Engineering

Nanomerics Ltd

Public / Non-Profit Organizations/Institutes

Aston Uni	Sekisui
Department for International Trade	UCB
BioPartner UK	UCLB
LiliumX	Univ. of Dundee
Nevrargenics Ltd	Univ. of Edinburgh
Ochre Bio	Vaccitech plc
Queen's University Belfast	

Unclassified

Absolute Antibody	ImmTune Therapies
Adaptimmune	InSilicoTrials Technologies
Advanced Clinical	Ipsen
Almac Group	Jazz Pharmaceuticals
AlphaSense	Labcorp Drug Development
Amphista	LifeSci Search
Apex Healthcare Consulting Limited	MediMab Biotherapeutics
Aptamer Group PLC	MediWales
Arix Bioscience	Merck KGaA
Asieris Pharmaceutical	Mergermarket
ASKA Pharmaceutical Co., Ltd.	MESOX (Spinout from Aston)
Astellas Pharma	Mills & Reeve LLP
Atheneum	Mitsubishi Tanabe Pharma Corporation
BioCentury	Monograph
Biogen	MSD
BioLife Group	Norgine Limited
Biomage Ltd	Oppilotech Ltd
Biopharma Excellence by PharmaLex	Ossianix
Bristol-Myers Squibb Company	Otsuka Pharmaceutical

Unclassified continued

Charles River Associates

Chiesi Ltd

Chugai Pharmaceutical Co., Ltd.

Curileum Discovery Ltd

Daewoong Pharmaceutical Co., Ltd.

Domainex Ltd.

éclateral Ltd

Edinburgh Molecular Imaging

Eli Lilly and Company

Emergex Vaccines

Esperante

Eurofins Discovery, DiscoveryOne

Evotec International GmbH

Evox Therapeutics

Exploristics

Ferring

Forcefield Therapeutics

GlobalData PLC

Gowling WLG

GSK

HungaroTrial CRO

HVIVO Services Limited - London

IAG (Image Analysis Group)

ICR

ImaginAb

Owkin

Pencil Biosciences

Pharma Intelligence

PharmaCircle

PHARMASSIST LTD

Precision for Medicine

ProPharma Group

Rallybio

Random42

RBW Consulting

ReNewVax Ltd

Sartorius Stedim Biotech

Shionogi

Silence Therapeutics plc

Simbec-Orion

Simcere Pharma

Sonrai Analytics

Standigm

Tanner Pharma

VaxEquity Ltd.

Veristat

X-Chem Inc

Supported events

ChinaBio Partnering Forum

08-11 Nov, Beijing & Digital

15% discount

BioTechX

08-09 Nov, Basel

20% discount

LSX Investival Showcase

14 Nov, London

15% discount

Pharma Integrates

17 Nov, London

Free passes available

Biotech Showcase 2023

09-11 Jan 2023, San Francisco

\$200USD discount available

BioPartner UK has negotiated exceptional discounts to some of the world's highest-quality biopharma partnering events. With the assistance of our alliance partners, we manage the UK presence at key overseas conferences.

BioPartner UK also recommends a number of investor conferences and internationally focused events

**See all of our recommended events
at biopartner.co.uk/events**

ANGLONORDIC

Life Science Conference



Anglonordic is by invitation, exclusively for European investors and R&D companies from the Nordics and the UK to connect with each other. With an established format of panel discussions, parallel technology and biotech investment rooms, plus 1:1 meetings, this conference provides exceptional value.



**BIO-Europe attendees
can save 20%**

Scan the QR code to request an invitation and use code **ANCBEU20**

ANGLONORDIC Life Science Conference



MEET decision makers at leading and upcoming drug discovery and technology companies from the UK and Nordic regions, along with investment firms from throughout Europe.

LEARN from major investment firms about the current status of European investment in life science technologies.

GAIN insights from experienced life science operators within the Anglo-Nordic space.



County Hall, London

20 April, 2023

8:15 AM – 6:30 PM

Investors attend **free of charge**

Delegate passes **only £500**

Service providers and CROs may attend as exhibitors or sponsors. See the options at:

www.anglonordiclifescience.com/page/sponsorship

Applications to pitch are open and will be selected in stages over the coming months.

£750+VAT includes your delegate pass. Apply at:

www.anglonordiclifescience.com/page/pitch



SDI.CO.UK



Scottish Development International along with
BioPartner UK invites you to a

MALT WHISKY AND GIN TASTING RECEPTION AT BIO-EUROPE



Monday
24TH
October

From
6 PM

Stand#19, Halle 2, adjacent to:
Congress Center Leipzig, Seehausener
Allee 1, 04356 Leipzig, Germany

We look forward to welcoming you.

